Fact CheckerSign in

NCT07758218Not yet recruitingPhase 1

Allogeneic iNKT Cell Therapy (agenT-797) After SCT

UW26004: Phase I Trial of Allogeneic iNKT Cell Therapy (agenT-797) in Patients Undergoing Allogeneic Hematological Stem Cell Transplantation (SCT)

Source: ClinicalTrials.gov · Last updated 29 Oct 2026

Brief summary (registry, in English)

The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are: * Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797? Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
22 (estimated)
First submitted
5 Aug 2026
Start date
Nov 2026
Primary completion date
Oct 2029
Lead sponsor
University of Wisconsin, Madison
NCT number
NCT07758218

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 22
  • From Nov 2026 to the primary completion date, Oct 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Excluded Diagnoses: Primary Myelofibrosis in the dose escalation phase and could be included in the dose-expansion phase

Who the study is looking for

  • Age ≥18 years at the time of consent
  • Adult patients anticipated to get an allogeneic hematopoietic cell transplantation (allo-SCT)
  • All donor types are accepted (MMUD \[mismatched unrelated donor\], MUD \[matched unrelated donor\], MSD \[matched sibling donor\], haploidentical)
  • All conditioning regimens will be accepted (MAC \[myeloablative conditioning\], RIC \[reduced-intensity conditioning\], NMAC \[non-myeloablative conditioning\])
  • Karnofsky Performance Scale (KPS) \> 70
  • Eligible Diagnoses:
    • Acute myeloid leukemia (AML) with intermediate/high-risk features or relapsed disease
    • Chronic myeloid leukemia (CML) in accelerated or blast phases
    • Myelodysplastic syndrome (MDS) with intermediate/high-risk features
    • Acute lymphoblastic leukemia (ALL) with high-risk features or relapsed disease
    • or any patients undergoing allogeneic stem cell transplant (allo-SCT) as standard of care could be eligible

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Wisconsin - Madison
Coordinator of this site? Confirm its status		MadisonUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.